Home/Pipeline/Valtoco (diazepam nasal spray)

Valtoco (diazepam nasal spray)

Acute treatment of seizure clusters

ApprovedActive

Key Facts

Indication
Acute treatment of seizure clusters
Phase
Approved
Status
Active
Company

About Neurelis

Neurelis is a private, commercial-stage biopharmaceutical company specializing in neurology, with a core focus on epilepsy. The company has built its portfolio around proprietary drug delivery enhancement technologies—Intravail®, ProTek®, and Hydrogel™—which enable non-invasive administration of therapeutics. Its lead commercial product is Valtoco® (diazepam nasal spray) for acute treatment of seizure clusters, and it maintains a pipeline of investigational neurology candidates. Neurelis operates with a patient-centric model, offering savings and support programs to ensure access to its therapies.

View full company profile

Therapeutic Areas